LATEST UPDATES » Vol 25, No. 07, July 2021 – Ageing Better – Breakthroughs and Innovations for a Greying World       » A Plant-Based Remedy for Big, Broken Hearts       » Fuelling the Future with Multi-Element Alloys and Green Hydrogen       » RADICA: A Radical, Rapid Method for Accurate Detection of Viruses       » Untangling the Twists of Alzheimer’s Plaques       » Turning Aquaculture Trash to Treasure for Tissue Repair      
Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
  • New R&D facility in Singapore will support healthcare emergency response
  • Reinforces Singapore's status as world's leading biomedical hub
Singapore, 13 May 2016 - Mundipharma has delivered another boost to the City State's booming biomedical sector, announcing a planned 7,300m2 facility in Tuas at an official groundbreaking ceremony attended by Minister of State for Trade & Industry, Dr. Koh Poh Koon today.

The new facility will be the world's first BETADINE® Consumer Health Hub that combines R&D, manufacturing and distribution. The povidone-iodine-based solution has been trusted by hospitals, doctors and consumers around the world for more than 60 years, and the new facility will produce the equivalent of approximately one billion applications of BETADINE® treatments annually to meet increased demand in the region.

In vitro studies have proven that BETADINE® kills the viruses associated with diseases including Ebola, MERS, SARS, Influenza and Hand Foot and Mouth Disease. Research shows that the number of outbreaks, and types of disease, have both increased significantly in recent times. Many, including Ebola, are difficult to predict, and their spread has been accelerated by travel, urbanisation and the interconnected nature of today's world.*

Manufacturing BETADINE® in Singapore will enable Mundipharma to respond quickly to regional health crises, while the R&D function will seek new solutions to meet the unique healthcare challenges faced by an increasingly globalised region.

Mundipharma President of Asia Pacific, Latin America, the Middle East & Africa, Raman Singh, said, "Given the accelerating demand for essential treatments, and 70 per cent of new demand projected to come from Asia, it's critical to have a strategically positioned manufacturing capability supported by an R&D function that is dedicated to unique characteristics of the region it supports.

Mundipharma, which already has its regional headquarters in Singapore, has achieved significant growth over the past four years, and is proud to be part of the city-state's dynamic business landscape.

"We welcome Mundipharma's strong commitment to Singapore. This is testament to Singapore's capabilities to partner companies in both the production and development of innovative medicines to address global healthcare needs. The vibrant Biomedical Sciences ecosystem in Singapore makes it a choice location for companies to carry out manufacturing, R&D and commercial headquarters activities in one place", said Ms. Weng Si Ho, Director, Biomedical Sciences, Singapore Economic Development Board (EDB).

A further demonstration of Mundipharma's commitment to the region, the highly-automated new facility will feature cutting-edge technology and house six BETADINE® production lines, creating demand for a range of jobs. The facility will be operational in January 2018.

*Neiderud CJ. Infect Ecol Epidemiol. 2015 Jun 24;5:27060. How urbanization affects the epidemiology of emerging infectious diseases. [https://www.infectionecologyandepidemiology.net/index.php/iee/article/view/27060] Accessed on 07 April 2016

About Mundipharma

Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, ophthalmology, respiratory disease, rheumatoid arthritis and antiseptics.

For more information please visit: www.mundipharma.com.sg


The BETADINE® (Povidone-Iodine) range of products is trusted by hospitals around the world for over 60 years to prevent and treat infections. A trusted brand among consumers at home to treat small wounds and grazes, sore throats, feminine infections and to stop minor problems from escalating into big issues. In-vitro studies show that Povidone-iodine, the key active ingredient of BETADINE® kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains that cause infections. BETADINE® has four main categories of products in Wound Care, Feminine Care, Throat / Oral Care and Infectious Diseases to meet the varying needs of our customers.

®: BETADINE is a registered trademark of Mundipharma

Source: WATATAWA & Mundipharma
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare
news Anti-Pandemic Forum to be Hosted by Top-Notch American and Chinese Scientists
news Commemorating World Health Day with Viatris
news Entire industrial chain resources of advanced medical equipment are lining up at Medtec China 2021

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy